If you have come across 5-Amino-1MQ listed alongside research peptides, the first thing worth clearing up is what it actually is — because it is frequently grouped with peptides it does not chemically resemble. This overview covers the identity of 5-Amino-1MQ, the enzyme it acts on, and strictly what published laboratory and animal studies have measured.
Is 5-Amino-1MQ a peptide? No
5-Amino-1MQ is a small molecule, not a peptide. A peptide is a chain of amino acids joined by peptide bonds; 5-Amino-1MQ has no amino acid backbone at all. According to PubChem (CID 950107), it is 5-amino-1-methylquinolinium — a derivative of the 1-methylquinolinium scaffold, an aromatic bicyclic ring system carrying an amino group. Its molecular formula is C₁₀H₁₁N₂⁺ (a positively charged quinolinium cation) with a molecular weight of approximately 159 g/mol. For comparison, even a short research peptide weighs several times that and is built from a completely different class of chemistry.
That distinction matters for how the compound is classified and discussed. The abbreviation “1MQ” refers to 1-methylquinolinium, and the “5-amino” prefix marks where the amino group sits on the ring. So when 5-Amino-1MQ appears next to peptides in a catalog, it is a small-molecule research chemical sharing shelf space, not chemical lineage.
The target: nicotinamide N-methyltransferase (NNMT)
5-Amino-1MQ is studied as an inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT is an enzyme, and understanding what it does is the key to understanding why researchers built molecules to block it.
NNMT transfers a methyl group from the universal methyl donor S-adenosylmethionine (SAM) onto nicotinamide (a form of vitamin B3), producing 1-methylnicotinamide and the byproduct S-adenosylhomocysteine. In other words, NNMT consumes two things the cell also uses elsewhere: a methyl donor and a precursor that feeds the NAD⁺ salvage pathway. A 2017 review in Trends in Endocrinology and Metabolism characterized NNMT as far more than a simple vitamin B3 clearance enzyme, describing its position at the intersection of cellular methylation capacity and NAD⁺ metabolism (Pissios, 2017).
Because NNMT sits at that junction, it became a candidate target in metabolic research:
- Methylation pathway: NNMT activity draws down SAM, the cell’s methyl-donor currency.
- NAD⁺ pathway: nicotinamide that NNMT methylates is no longer available for recycling back into NAD⁺.
An inhibitor of NNMT is therefore a tool for asking what happens, in a research model, when that enzymatic draw is reduced.
What the genetic studies measured first
The interest in blocking NNMT pharmacologically traces back to a genetic experiment. In a 2014 study published in Nature, researchers used antisense oligonucleotides to knock down NNMT expression in mice. They reported that reducing NNMT in white adipose tissue and liver altered the availability of adipose SAM and NAD⁺ and changed the metabolic profile of the diet-challenged animals relative to controls (Kraus et al., 2014). The study established NNMT as a metabolically active node in those mouse tissues rather than an inert clearance enzyme.
That genetic result is what motivated the search for a small molecule that could reproduce the same enzyme block without altering the gene — which is where 5-Amino-1MQ enters the literature.
What 5-Amino-1MQ studies measured in research models
In a 2018 paper in Biochemical Pharmacology, investigators characterized 5-Amino-1MQ as a selective, membrane-permeable small-molecule NNMT inhibitor and tested it in mice maintained on a high-fat diet. The authors reported that, in this diet-induced model, the compound was associated with measured reductions in body weight and white adipose mass relative to control animals, which they attributed to changes in adipocyte energy handling rather than to reduced food intake (Neelakantan et al., 2018). These are findings measured in mice in a controlled study — not statements about people.
The proposed biochemical rationale, as discussed in that work and the surrounding literature, runs through the two pathways above: with NNMT inhibited, less nicotinamide is methylated and more remains available to the NAD⁺ salvage pathway, and less SAM is consumed for that methylation. The studies report enzyme inhibition and downstream metabolic readouts in cell and animal systems; they do not translate into a human result, and this overview makes no such claim.
NNMT inhibition has also been examined outside the obesity model. In a 2019 study, again in Biochemical Pharmacology, a small-molecule NNMT inhibitor was reported to activate senescent muscle stem cells and to improve the regenerative capacity of aged skeletal muscle in a mouse injury model, which the authors connected to NAD⁺ availability in the satellite-cell niche (Neelakantan et al., 2019). As with the metabolic work, these are measurements in aged mice, framed here only as what the cited study observed.
Where 5-Amino-1MQ sits as a research chemical
Pulling the chemistry and the pharmacology together gives a clear identity:
- Class: small molecule (a 1-methylquinolinium derivative), not a peptide.
- Mechanism studied: inhibition of the enzyme NNMT.
- Research context: NAD⁺ and SAM-dependent methylation metabolism in cell-culture and rodent models.
That last point is the operative one for anyone evaluating the published record: every effect described in the primary literature is an effect measured in a research system — cultured adipocytes, diet-challenged mice, aged mouse muscle — with a citation attached. 5-Amino-1MQ is a laboratory research compound, and the data on it should be read as exactly that.
Frequently asked questions
Is 5-Amino-1MQ a peptide?
No. 5-Amino-1MQ is a small molecule — a 1-methylquinolinium derivative (PubChem CID 950107, formula C₁₀H₁₁N₂⁺, about 159 g/mol). It has no amino acid backbone and is not a peptide, even though it is often listed alongside peptides.
What does NNMT stand for?
NNMT stands for nicotinamide N-methyltransferase, an enzyme that transfers a methyl group from S-adenosylmethionine (SAM) onto nicotinamide (a form of vitamin B3). 5-Amino-1MQ is studied as an inhibitor of this enzyme.
What does 5-Amino-1MQ do to NNMT?
In published research it acts as a selective, membrane-permeable inhibitor of NNMT — it reduces the enzyme’s activity. Researchers use it as a chemical tool to study what reduced NNMT activity does in cell and animal models (Neelakantan et al., 2018).
Why is 5-Amino-1MQ connected to NAD⁺?
NNMT methylates nicotinamide, a precursor the NAD⁺ salvage pathway also uses. By inhibiting NNMT, studies report that more nicotinamide remains available for NAD⁺ metabolism in the model systems examined (Pissios, 2017). This describes the proposed biochemistry in research, not an outcome in people.
What have studies measured with 5-Amino-1MQ?
In diet-induced obese mice, a 2018 study measured reductions in body weight and white adipose mass attributed to adipocyte energy handling (Neelakantan et al., 2018). A 2019 study measured activation of aged muscle stem cells in mice (Neelakantan et al., 2019). These are measurements in research models only.
References
- Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology. 2018. PMID: 29155147.
- Kraus D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014. PMID: 24717514.
- Pissios P. Nicotinamide N-Methyltransferase: More Than a Vitamin B3 Clearance Enzyme. Trends in Endocrinology and Metabolism. 2017. PMID: 28291578.
- Neelakantan H, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochemical Pharmacology. 2019. PMID: 30753815.
For research use only. The products and materials discussed are intended for laboratory research purposes and are not for human or veterinary use, diagnosis, or treatment. This article describes the chemical structure and published pharmacological research of a compound and does not constitute a claim of any effect in any individual.
